Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line

Figure 1

Effects of HDAC and PARP inhibitors on SW1736 cell viability. Cells were treated for 72 h with SAHA (1 μM–4 μM) or PJ34 (5 μM–30 μM), and CellTiter-Blue Cell Viability assay was performed as described in Section 2. Bars indicate the percentage of viable cells versus controls (untreated cells) and represent means ± SD of three experiments. * indicates values significantly different compared to control.